Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.

randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure Mihai Gheorghiade, MD, Wendy A. Gattis, PharmD, Alejandro Barbagelata, MD, Kirkwood F. Adams, Jr, MD, Uri Elkayam, MD, Cesare Orlandi, MD, and Christopher M. O’Connor, MD, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Chicago, Ill, Durham and Chapel Hill, NC, Los Angeles, Calif, Buenos Aires, Argentina, and Baltimore, Md